<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126423</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT02126423</nct_id>
  </id_info>
  <brief_title>Resistance to Antibiotics in Patients Receiving Eye Injections</brief_title>
  <official_title>Prospective Study on Antimicrobial Resistance Rates Following Repeated Courses of Topical Antibiotics for Intravitreal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prism Vision Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prism Vision Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of short courses of topical antibiotic drops before and/or after&#xD;
      intravitreal injections is a common practice, but increasing evidence suggests this may not&#xD;
      lower the risk of infectious endophthalmitis and could increase rates of antimicrobial&#xD;
      resistance. The purpose of the present study is to determine the antimicrobial resistance&#xD;
      profiles in patients who have received numerous (≥ 20) courses of antibiotics for&#xD;
      intravitreal injection compared with untreated controls.&#xD;
&#xD;
      This study compares 20 control patients without prior intravitreal injection to 20 patients&#xD;
      who have undergone ≥ 20 prior intravitreal injections accompanied by a course of topical&#xD;
      antibiotics for two days before and/or after the injection procedure. The lower, inner eyelid&#xD;
      and nasal cavity were cultured and evaluated via disk diffusion method for antimicrobial&#xD;
      sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before administration of anti-VEGF therapy (Vascular Endothelial Growth Factor) or topical&#xD;
      antibiotics, conjunctival and nasopharyngeal swabs are procured with the Bacti-Swab transport&#xD;
      system (Thermo Fisher Scientific, Waltham, MA). For conjunctival samples, a sterile swab is&#xD;
      moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from&#xD;
      the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For&#xD;
      nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against&#xD;
      the anterior nasal mucosa for 3 seconds.&#xD;
&#xD;
      Culture swabs are then plated onto 5% sheep blood plates and incubated at 37°C for 3 days.&#xD;
      Colonies are isolated and identified with API (Analytical Profile Index) Microbial&#xD;
      Identification Kits (bioMérieux Inc., Hazelwood, MO). Antibiotic susceptibility is determined&#xD;
      using the Kirby Bauer disc diffusion method. Additional data collected includes age, ocular&#xD;
      and systemic medical conditions, and the number of intravitreal injections along with&#xD;
      anti-VEGF agents used.&#xD;
&#xD;
      Statistical calculations for antibiotic resistance comprises of t-test and and multivariate&#xD;
      analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kirby Bauer disc diffusion antimicrobial susceptibility</measure>
    <time_frame>15 minutes</time_frame>
    <description>One set of conjunctival and nasopharyngeal swabs obtained from patient shortly after recruitment. Antibiotic susceptibility is determined using the Kirby Bauer disc diffusion method for the following antibiotics: amoxicillin/clavulanate, cefazolin, cefoxitin, erythromycin, moxifloxacin, trimethoprim/sulfamethoxazole, linezolid, clindamycin, and doxycycline.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1st intravitreal injection</arm_group_label>
    <description>Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt;20 intravitreal injections</arm_group_label>
    <description>Conjunctival and nasopharyngeal swabs are obtained from each patient with &gt;20 intravitreal injection therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conjunctival and nasopharyngeal swabs</intervention_name>
    <description>For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.</description>
    <arm_group_label>1st intravitreal injection</arm_group_label>
    <arm_group_label>&gt;20 intravitreal injections</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Conjunctival and nasopharyngeal swabs are procured from each patient.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient setting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (above age 18) diagnosed with age-related macular degeneration and&#xD;
             receiving their 1st or 20th (or &gt;20th) intravitreal injection therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with current use of topical or systemic antibiotics and an active ocular&#xD;
             infection or ocular surface disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Fine, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NJ Retina</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Resistance, Microbial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

